NICE gains wider public health role
pharmafile | December 7, 2011 | News story | Sales and Marketing | NICE
NICE is to gain new powers to advise local authorities in England and Wales about public health.
From 2013 responsibility for public health will be passed from PCTs (which are to be abolished) to local government as part of the NHS reforms.
Today NICE has said that it will be responsible for producing new ‘Local Government Public Health Briefings’ to help promote best practice across the country. The new guidance will be “tailored practical advice” for local councillors, Directors of Public Health and other local government staff which can be adapted to local needs.
The Briefings will not be entirely new, but instead will distil existing NICE guidance on a range of key topics such as tackling tobacco and obesity, increasing physical activity, and topics on alcohol and health, and workplace health.
The Institute said it would aim to make it “easier for directors of public health, elected members and senior officers in local authorities to find out which public health actions are most effective whilst also providing the best value for money”.
Professor Mike Kelly, director of the centre for public health excellence at NICE, said: “This new area of work is in addition to our ongoing programme producing public health guidance.
The briefings are intended to help highlight public health approaches that are proven to be effective, and how they can not only improve the health of local people, but also save money.
Public health is key to cost-effectiveness
The announcement comes as the Journal of Public Health publishes a paper, written by NICE, highlighting the evidence that public health interventions are good value for money.
This paper is the first comprehensive list of cost-effectiveness estimates for public health interventions in England.
Professor Kelly, who also co-authored the article in the JPH, said that given the current economic climate, it was even more important than ever to make best use of limited resources.
“This research not only proves unequivocally that prevention is better than cure, but just how highly cost-effective the public health interventions recommended by NICE really are.
“A huge 85% of public health interventions were cost-effective at a threshold of £20,000 per quality-adjusted life year – this is considerably less than the extra cost per unit of health gained that the NHS often pays for clinical interventions, such as drug treatments.
“With this clear indication of the value of public health action, and its potential to save resources whilst improving health, we look forward to extending our portfolio of public health products to provide more support to the local government sector,” he concluded.
Ben Adams
Related Content
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Dual immunotherapy for bowel cancer now available under NHS
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in …
